TRβ Agonism Induces Tumor Suppression and Enhances Drug Efficacy in Anaplastic Thyroid Cancer in Female Mice
Endocrinology · 2023
DOI: 10.1210/endocr/bqad135 ↗Kurz gefasst
Fachartikel in der Zeitschrift Endocrinology, 2023. Verfasst von Noelle E Gillis und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacology, Larner College of Medicine, University of Vermont, Burlington, VT 05405, USA. Hauptthemen laut MEDLINE: Thyroid Carcinoma, Anaplastic, Thyroid Neoplasms. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, NIGMS NIH HHS, NIH HHS.
Abstract (Originalsprache)
Thyroid hormone receptor beta (TRβ) is a recognized tumor suppressor in numerous solid cancers. The molecular signaling of TRβ has been elucidated in several cancer types through re-expression models. Remarkably, the potential impact of selective activation of endogenous TRβ on tumor progression remains largely unexplored. We used cell-based and in vivo assays to evaluate the effects of the TRβ agonist sobetirome (GC-1) on a particularly aggressive and dedifferentiated cancer, anaplastic thyroid cancer (ATC). Here we report that GC-1 reduced the tumorigenic phenotype, decreased cancer stem-like cell populations, and induced redifferentiation of the ATC cell lines with different mutational backgrounds. Of note, this selective activation of TRβ amplified the effects of therapeutic agents in blunting the aggressive cell phenotype and stem cell growth. In xenograft assays, GC-1 alone inhibited tumor growth and was as effective as the kinase inhibitor, sorafenib. These results indicate that selective activation of TRβ not only induces a tumor suppression program de novo but enhances the effectiveness of anticancer agents, revealing potential novel combination therapies for ATC and other aggressive solid tumors.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacology, Larner College of Medicine, University of Vermont, Burlington, VT 05405, USA.
- University of Vermont Cancer Center, University of Vermont, Burlington, VT 05405, USA.
ORCID-Profile: Noelle E Gillis, Frances E Carr
Förderung
- NCI NIH HHS
- NIGMS NIH HHS
- NIH HHS
- National Institutes of Health
- National Cancer Institute
Zitieren
APA
Gillis, N. E., Cozzens, L. M., Wilson, E. R., Smith, N. M., Tomczak, J. A., Bolf, E. L., & Carr, F. E. (2023). TRβ Agonism Induces Tumor Suppression and Enhances Drug Efficacy in Anaplastic Thyroid Cancer in Female Mice. Endocrinology. https://doi.org/10.1210/endocr/bqad135
Vancouver
Gillis NE, Cozzens LM, Wilson ER, Smith NM, Tomczak JA, Bolf EL, et al. TRβ Agonism Induces Tumor Suppression and Enhances Drug Efficacy in Anaplastic Thyroid Cancer in Female Mice. Endocrinology. 2023. doi:10.1210/endocr/bqad135
BibTeX
@article{Gillis2023,
author = {Gillis, Noelle E and Cozzens, Lauren M and Wilson, Emily R and Smith, Noah M and Tomczak, Jennifer A and Bolf, Eric L and Carr, Frances E},
title = {TRβ Agonism Induces Tumor Suppression and Enhances Drug Efficacy in Anaplastic Thyroid Cancer in Female Mice},
journal = {Endocrinology},
year = {2023},
doi = {10.1210/endocr/bqad135}
}
EUVIMED